Learning curves in the current clinical biosimilar development

Many biosimilar developers need to think outside the box when structuring their clinical trials. As an example, one could discuss with a supervisor whether it is insufficient to investigate only one indication in the comparative efficacy study and rely on extrapolation for the remaining indications.

https://www.biosimilardevelopment.com/doc/biosimilar-clinical-trials-past-present-and-near-future-0001?vm_tId=2217396&user=89697b4a-1dcf-4952-afdc-6c787be708bf&vm_alias=Biosimilar%20Clinical%20Trials%3A%20Past,%20Present,%20And%20(Near)%20Future%20&utm_source=mkt_BIOS&utm_medium=email&utm_campaign=BIOS_06-04-2020&utm_term=89697b4a-1dcf-4952-afdc-6c787be708bf&utm_content=Biosimilar%20Clinical%20Trials%3A%20Past,%20Present,%20And%20(Near)%20Future%20&mkt_tok=eyJpIjoiWTJKbU1XRTBOek0yTkdFdyIsInQiOiJGZldMcUI4Rm1kSWZ3V1l2VWZQdGF3SlZacTZkRUoyd2RkMEZTOWRlRWpnVTRJVFdXOUNvaUJrNkNCVUpZQVpveE9Va3FEUWxiRStiMjFnVVlLZTB2QUI5aUMzbnNuUUxHNk1TZ2gzczNiS3ltMTd1bWNrTm1kRGd1SEdxRjNBUiJ9